Patent · US Active

Triazine based radiopharmaceuticals and radioimaging agents

US10086096B2 · kind B2 · utility

2Cited by
27References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 20, 2017
Grant dateOct 2, 2018
Priority date—
Expiry dateApr 20, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07F5/003
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.